8th June 2022 | Pharma Updates
Every single patient in this small-scale drug trial saw their cancer fade away
The drug given is called dostarlimab and is sold under the brand name Jemperli. It is an immunotherapy drug used to treat endometrial cancer, but this was the first clinical trial to see if it could also be used to treat rectal cancer tumours.
Procuring "Quality Assured" generics poses number of difficulties
Dr. Suresh Saravdekar, Ex-Assistant Director, Maharashtra Ministry of Medical Education and Health examines why procuring quality generic medicines is a challenge even in the “pharmacy of the world, ” and proposes policy changes to address the issue.
TN placed Abbott Pharmaceuticals on five-year blacklist
Abbott Healthcare has been blacklisted for five years by the Tamil Nadu Medical Services Corporation for concealing the fact that it has been banned by the Directorate General of Health Services and Employees’ State Insurance Corporation.
Lybrate acquired by Pristyn Care
Pristyn Care, a healthcare provider, has announced the acquisition of Lybrate, a health-tech platform, for an undisclosed sum in order to improve overall healthcare delivery and expand into primary care.
BI receives ad-interim injunctions againstfour Indian pharmaceutical companies
Boehringer Ingelheim (BI) has obtained ad interim injunctions against Eris Lifesciences, Emcure Pharma, Optimus Pharma, and MSN Laboratories, four domestic pharmaceutical companies.
Zydus Lifesciences received final FDA approval for an acne treatment gel
USFDA has given Zydus Lifesciences final approval to market Adapalene and Benzoyl Peroxide topical gel. The topical gel is a generic version of the drug Epiduo Forte, which is a US reference listed drug.
First biologic medicine for children with atopic dermatitis approved by FDA
Dupixent (dupilumab) has been approved by the Food and Drug Administration (FDA) for children aged 6 months to 5 years who have moderate-to-severe atopic dermatitis and are unable or unwilling to use topical prescription therapies.
You must be logged in to post a comment.